ArticleFrontiers in pharmacology2026
Integrating network toxicology and in vitro validation to elucidate PET microplastic-induced osteoarthritis pathogenesis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to elucidate the molecular mechanisms through which PET microplastics (PET-MP) influence osteoarthritis (OA) pathogenesis by integrating network toxicology, machine learning, and Methods: Differential gene expression analysis and WGCNA were applied to multiple OA datasets to identify disease-related targets. PET-MP biological targets were predicted via ChEMBL, SwissTargetPrediction, and PharmMapper. Overlapping targets were screened using machine learning algorithms, and molecular docking was performed to assess binding interactions. Results: A total of 452 PET-associated targets were identified, with 12 core PET-MP-OA genes established through intersection analysis. Functional enrichment implicated the NF-κB and IL-17 signaling pathways. Machine learning screening based on feature importance and SHAP values prioritized six hub genes: AKR1A1, INSR, KIF11, MMP1, KCNN4, and TK1. Molecular docking generated predicted AutoDock Vina scores ranging from -3.893 to -7.434 kcal/mol. Conclusion: PET-MP may promote OA progression by disrupting molecular pathways related to inflammation, oxidative stress, and cartilage degradation. The identified hub genes offer new insights into microplastic toxicology in joint disease and represent potential therapeutic targets and biomarkers for PET-MP-induced OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.